An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs
- 22 September 2013
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 72 (6) , 1361-1367
Abstract
Trastuzumab has deeply and radically changed the course of HER2-positive breast cancer disease. The recent development of a subcutaneous (SC) formulation of trastuzumab is an important step towards improved patients’ care. SC trastuzumab at a fixed dose of 600 mg administered every 3 weeks for about 5 min provides a valid alternative to the IV, both in terms of efficacy and safety. This results in substantial time savings for patients, pharmacists, physicians and nursing staff, with a healthcare professionals’ and patients’ preference largely going to SC. In addition, the possibility to treat patients with poor venous access or to spare patients’ venous capital when necessary may also be of interest.Keywords
This publication has 18 references indexed in Scilit:
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyThe Lancet Oncology, 2013
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast CancerThe Journal of Clinical Pharmacology, 2013
- How do patients with inflammatory bowel disease want their biological therapy administered?BMC Gastroenterology, 2010
- Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteersCurrent Medical Research and Opinion, 2009
- Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)Rheumatology, 2009
- The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients with Advanced IllnessJournal of Pain and Symptom Management, 2009
- Assessing the Role of Human Recombinant Hyaluronidase in Gravity-Driven Subcutaneous Hydration: The INFUSE-LR StudyJournal of Palliative Medicine, 2007
- Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administrationExpert Opinion on Drug Delivery, 2007
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Dose Scheduling – Herceptin®Oncology, 2001